Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Kaftrio/Trikafta in cystic fibrosis with non-F508del ELX/TEZ/IVA-responsive CFTR mutations
NL-OMON51518Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Kaftrio + ivacaftor with Placebo (2 arms). Primary endpoint: Absolute change from baseline in percent predicted forced expiratory volume in 1 second. Started May 2022; status: completed.
02
Drugs
elexacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON51518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51518.